Physician profile
Stephen Rubenstein
NPI 1467424044
$653.27
in general payments reported to CMS, 2019-2025
17 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $17.79 · 2021: $25.30 · 2022: $56.52 · 2023: $12.75 · 2024: $90.73 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $96.22 | 2025 | Clonoseq |
| Astrazeneca Pharmaceuticals Lp | $84.39 | 2019 | |
| Myovant Sciences INC. | $81.82 | 2021-2022 | |
| Beigene USA, INC. | $81.50 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $54.30 | 2025 | Enhertu |
| Genzyme Corporation | $52.77 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $50.14 | 2024-2025 | Monoferric |
| Janssen Scientific Affairs, LLC | $26.55 | 2019 | |
| Celgene Corporation | $22.97 | 2019 | |
| Lilly USA, LLC | $20.27 | 2024 | Verzenio, Jaypirca, Retevmo |
| Agios Pharmaceuticals, INC. | $19.92 | 2024 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.79 | 2020 | |
| Janssen Biotech, INC. | $13.13 | 2019 | |
| Amgen INC. | $12.75 | 2023 | Prolia, Evenity |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.